Periphagen Overview

  • Status
  • Private

Periphagen General Information


Developer of biopharmaceutical products intended to treat nuerological disorders thereby improving patients' quality of life. The company's Nueronal Therapeutics (NET) platform can express gene constructs in discrete regions of the nervous system following a simple intradermal injection, providing patients treatment specificity and substantially reduced systemic adverse effects.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 2403 Sidney Street
  • Suite 255
  • Pittsburgh, PA 15203
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Periphagen Board Members (1)

Name Representing Role Since
Peter Lanciano Periphagen Chairman 000 0000
To view Periphagen’s complete board members history, request access »

Periphagen Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 (000000 08-Oct-2012 000000000000000000 0000 Biotechnology
To view Periphagen’s complete acquisitions history, request access »

Periphagen Subsidiaries (1)

Company Name Industry Location Founded
0000000000 (000000 Biotechnology Pittsburgh, PA 0000
To view Periphagen’s complete subsidiaries history, request access »